GET DAILY SIGNALSORIC Pharmaceuticals (ORIC) Q3 2026 Earnings: Clinical Updates and Cash Position in Focus
Key Takeaways
- ORIC Pharmaceuticals is expected to report third-quarter 2026 results after market close on November 12, 2026, though the date has not yet been formally confirmed by the company.
- As a clinical-stage oncology company, ORIC generates no product revenue, so investor attention will center on the net loss per share and research and development (R&D) spending.
- Wall Street consensus estimates point to a net loss of roughly $0.38 to $0.40 per share for the quarter ended September 30, 2026.
- The headline focus will be enrollment and operational updates for the Himalayas-1 Phase 3 trial of rinzimetostat in metastatic castration-resistant prostate cancer (mCRPC).
- Cash, cash equivalents, and investments totaled $387.6 million as of June 30, 2026, with runway expected to fund operations into the second half of 2028.
- For additional context on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages for a fuller picture.
- Readers looking for broader market ideas can also explore Trending AI Robots for data-driven trading signals.
Why the Upcoming Report Matters
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on overcoming cancer treatment resistance. With no marketed products, its quarterly report centers more on cash management and clinical execution than on revenue. The third-quarter update arrives shortly after the company initiated Himalayas-1, a global Phase 3 registrational trial for its lead candidate rinzimetostat in mCRPC, a setting where existing androgen-receptor therapies often lose effectiveness. Rising R&D costs tied to that roughly 600-patient study have widened the company's losses, making expense discipline and cash runway a central theme. Investors will be watching for confirmation that spending remains aligned with the company's runway guidance into the second half of 2028. I also checked this using Tickeron’s AI Screener to see how ORIC compares to others in the industry.
Earnings Estimates and Recent Trends
Analysts expect ORIC to report a net loss of approximately $0.38 to $0.40 per share for the third quarter of 2026, with essentially no revenue given the company's clinical-stage status. For comparison, ORIC reported a loss of $0.33 per share in the third quarter of 2025, beating the $0.40 consensus at the time. In the most recent quarter, the second quarter of 2026, the company posted a loss of $0.38 per share, slightly wider than the $0.36 consensus, driven by higher R&D expenses related to the advancement of rinzimetostat and its second program, enozertinib, a brain-penetrant EGFR (epidermal growth factor receptor) inhibitor for non-small cell lung cancer (NSCLC). Beyond the headline loss figure, investors will monitor total operating expenses, the pace of R&D spending, and the cash balance.
Market Sentiment and Pipeline Progress
Sentiment heading into ORIC's third-quarter report has been shaped primarily by pipeline progress rather than the headline loss. The initiation of the Himalayas-1 Phase 3 trial, along with clinical trial collaboration agreements with Bayer and Johnson & Johnson for rinzimetostat supply, has reinforced confidence in the company's lead program. At the same time, a strategic pipeline prioritization and a 20% workforce reduction completed in late 2025 signaled a sharper focus on cash efficiency. Key risks to monitor around the print include any increase in the expected burn rate from the global trial's ramp-up, changes to the cash runway projection, and any commentary on the timing of the rinzimetostat program update the company has guided for the second half of 2026.
Forward Outlook and Items to Track
The most important forward-looking items for ORIC are clinical, not financial. Management has guided to a rinzimetostat program update in the second half of 2026, and investors will be listening for details on enrollment progress in Himalayas-1, which spans more than 250 sites across 25 countries. The trial's primary endpoint is radiographic progression-free survival, with overall survival as a key secondary endpoint, and results are not expected until later in the decade.
On the cost side, R&D expense is likely to climb as the Phase 3 trial reaches full enrollment speed. Investors should watch whether the company's cash position—$387.6 million as of June 30, 2026—remains consistent with the stated runway into the second half of 2028. Any revision to that guidance would be a material signal.
For the enozertinib program, updates on the Phase 1b trials in patients with EGFR exon 20 insertion and atypical mutations in NSCLC remain secondary catalysts worth monitoring. Overall, the report is best viewed as a checkpoint on clinical execution and capital discipline rather than a traditional earnings event.
AI Tools in My Research Workflow
When preparing for reports like this one, I often rely on Tickeron’s AI Screener to scan for comparable biotech names and assess technical and fundamental signals side by side. It helps me quickly surface sector peers and review volatility patterns without manual effort, giving additional context on how ORIC fits within the broader group.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ORIC's RSI Oscillator descends into oversold zone
The RSI Oscillator for ORIC moved into overbought territory on November 13, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +8.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where ORIC advanced for three days, in 214 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
ORIC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ORIC as a result. In 62 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The Moving Average Convergence Divergence Histogram (MACD) for ORIC turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 37 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
ORIC moved below its 50-day moving average on October 26, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORIC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.398) is normal, around the industry mean (3.498). P/E Ratio (-6.785) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. ORIC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORIC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical stage company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance
Industry Biotechnology
Advertisement